Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EGRX Eagle Pharmaceuticals	$3.69 -0.9%	$2.50	$1.50 ▼ $3.87	$47.92M	0.83	7,833 shs	1,332 shs
JSPR Jasper Therapeutics	$3.37 +0.6%	$5.07	$2.27 ▼ $26.05	$50.32M	2.69	401,746 shs	383,600 shs
SAVA Cassava Sciences	$2.10 +1.4%	$2.04	$1.15 ▼ $42.20	$100M	-2.04	2.80 million shs	666,120 shs
VTGN VistaGen Therapeutics	$2.54 +2.8%	$2.30	$1.90 ▼ $4.01	$72.02M	0.61	190,826 shs	417,009 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EGRX Eagle Pharmaceuticals	+0.27%	+2.74%	+59.57%	+108.33%	-37.60%
JSPR Jasper Therapeutics	+1.21%	-8.97%	-40.50%	-15.62%	-84.49%
SAVA Cassava Sciences	+0.49%	-5.48%	+0.98%	+43.75%	-84.70%
VTGN VistaGen Therapeutics	+9.78%	-0.80%	+4.66%	+17.06%	-35.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EGRX Eagle Pharmaceuticals	2.4689 of 5 stars	0.0	3.0	3.9	0.6	3.3	0.0
JSPR Jasper Therapeutics	3.7161 of 5 stars	4.3	4.0	0.0	3.0	1.7	0.6
SAVA Cassava Sciences	4.1746 of 5 stars	3.3	3.0	4.7	2.7	0.0	1.3
VTGN VistaGen Therapeutics	0.6398 of 5 stars	0.0	1.0	0.0	3.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
JSPR Jasper Therapeutics	2.60	Moderate Buy	$29.75	782.79% Upside
SAVA Cassava Sciences	2.50	Moderate Buy	$54.50	2,495.24% Upside
VTGN VistaGen Therapeutics	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest EGRX, SAVA, VTGN, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	VTGN VistaGen Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EGRX Eagle Pharmaceuticals	$257.55M	0.19	$9.23 per share	0.40	N/A	∞
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A
VTGN VistaGen Therapeutics	$490K	151.16	N/A	N/A	$2.44 per share	1.04

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-109.45%	-89.82%	8/12/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$1.50	N/A	N/A	N/A	N/A	-87.72%	-72.05%	8/14/2025 (Estimated)
VTGN VistaGen Therapeutics	-$51.42M	-$1.66	N/A	N/A	N/A	-6,777.08%	-58.88%	-52.38%	8/12/2025 (Estimated)

Latest EGRX, SAVA, VTGN, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.28	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q1 2026	VTGN VistaGen Therapeutics	-$0.46	N/A	N/A	N/A	$0.22 million	N/A
6/17/2025	Q4 2025	VTGN VistaGen Therapeutics	-$0.52	-$0.43	+$0.09	-$0.43	$0.18 million	($0.01) million
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	SAVA Cassava Sciences	N/A	-$0.48	N/A	-$0.48	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	4.31	4.31
SAVA Cassava Sciences	N/A	9.08	9.08
VTGN VistaGen Therapeutics	N/A	6.51	6.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EGRX Eagle Pharmaceuticals	85.36%
JSPR Jasper Therapeutics	79.85%
SAVA Cassava Sciences	38.05%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
EGRX Eagle Pharmaceuticals	28.90%
JSPR Jasper Therapeutics	4.60%
SAVA Cassava Sciences	2.40%
VTGN VistaGen Therapeutics	1.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable
SAVA Cassava Sciences	30	48.31 million	47.15 million	Optionable
VTGN VistaGen Therapeutics	40	29.16 million	28.78 million	Optionable

EGRX, SAVA, VTGN, and JSPR Headlines

Recent News About These Companies

VistaGen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50-Day Moving Average - Time to Sell?

July 16 at 5:58 AM | marketbeat.com

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

July 15 at 8:42 AM | businesswire.com

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

July 15 at 8:42 AM | businesswire.com

Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay

July 3, 2025 | msn.com

VTGN Vistagen Therapeutics, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

June 25, 2025 | businesswire.com

Vistagen Therapeutics, Inc. (VTGN) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

William Blair Issues Negative Forecast for VTGN Earnings

June 23, 2025 | marketbeat.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript

June 22, 2025 | insidermonkey.com

William Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)

June 20, 2025 | theglobeandmail.com

Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges

June 19, 2025 | tipranks.com

What is William Blair's Forecast for VTGN Q1 Earnings?

June 19, 2025 | marketbeat.com

VistaGen Therapeutics (NASDAQ:VTGN) Earns "Outperform" Rating from William Blair

June 18, 2025 | marketbeat.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ...

June 18, 2025 | finance.yahoo.com

Vistagen Therapeutics Reports Progress in Clinical Trials

June 17, 2025 | tipranks.com

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

June 17, 2025 | seekingalpha.com

Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

June 17, 2025 | marketbeat.com

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

June 17, 2025 | businesswire.com

Insights into VistaGen Therapeutics's Upcoming Earnings

June 16, 2025 | benzinga.com

Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For

June 16, 2025 | gurufocus.com

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

June 12, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX, SAVA, VTGN, and JSPR Company Descriptions

Eagle Pharmaceuticals NASDAQ:EGRX

$3.69 -0.04 (-0.94%)

As of 12:38 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Jasper Therapeutics NASDAQ:JSPR

$3.37 +0.02 (+0.60%)

Closing price 04:00 PM Eastern

Extended Trading

$3.40 +0.03 (+1.04%)

As of 07:54 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Cassava Sciences NASDAQ:SAVA

$2.10 +0.03 (+1.45%)

Closing price 04:00 PM Eastern

Extended Trading

$2.10 0.00 (-0.24%)

As of 07:44 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

VistaGen Therapeutics NASDAQ:VTGN

$2.54 +0.07 (+2.83%)

Closing price 04:00 PM Eastern

Extended Trading

$2.54 +0.00 (+0.20%)

As of 07:59 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time